The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback